Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherShort Communication

IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE O-DEMETHYLATION OF THE DESIGNER DRUG P-METHOXYMETHAMPHETAMINE

Roland F. Staack, Denis S. Theobald, Liane D. Paul, Dietmar Springer, Thomas Kraemer and Hans H. Maurer
Drug Metabolism and Disposition April 2004, 32 (4) 379-381; DOI: https://doi.org/10.1124/dmd.32.4.379
Roland F. Staack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis S. Theobald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liane D. Paul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dietmar Springer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Kraemer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans H. Maurer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

p-Methoxymethamphetamine (PMMA) is a new designer drug, listed in many countries as a controlled substance. Several fatalities have been attributed to the abuse of this designer drug. Previous in vivo studies using Wistar rats had shown that PMMA was metabolized mainly by O-demethylation. The aim of the study presented here was to identify the human hepatic cytochrome P450 (P450) enzymes involved in the biotransformation of PMMA to p-hydroxymethamphetamine. Baculovirus-infected insect cell microsomes, pooled human liver microsomes (pHLMs), and CYP2D6 poor-metabolizer genotype human liver microsomes (PM HLMs) were used for this purpose. Only CYP2D6 catalyzed O-demethylation. The apparent Km and Vmax values in baculovirus-infected insect cell microsomes were 4.6 ± 1.0 μM and 92.0 ± 3.7 pmol/min/pmol P450, respectively, and 42.0 ± 4.0 μM and 412.5 ± 10.8 pmol/min/mg protein in pHLMs. Inhibition studies with 1 μM quinidine showed significant inhibition of the metabolite formation (67.2 ± 0.6%; p < 0.0001), and comparison of the metabolite formation between pHLMs and PM HLMs revealed significantly lower metabolite formation in the incubations with PM HLMs (87.3 ± 1.1%; p < 0.0001). According to these studies, CYP2D6 is the major P450 involved in O-demethylation of PMMA.

Footnotes

  • ↵1 Abbreviations used are: PMMA, p-methoxymethamphetamine, International Union of Pure and Applied Chemistry (IUPAC): [1-(4-methoxyphenyl)propane-2-yl](methyl)azane); MDMA, methylenedioxymethamphetamine, IUPAC: [1-(1,3-benzodioxol-5-yl)propane-2-yl](methyl)azane; HO-MA, p-hydroxymethamphetamine, IUPAC: [1-(4-hydroxyphenyl)propane-2-yl](methyl)azane; P450, cytochrome P450; pHLM, pooled human liver microsome; PM HLM, CYP2D6 poor-metabolizer genotype human liver microsome; HO-AM, p-hydroxyamphetamine, IUPAC: 1-(4-hydroxyphenyl)propane-2-ylazane); IS, internal standard; LC-MS, liquid chromatography-mass spectrometry; PM, CYP2D6 poor metabolizer; EM, CYP2D6 extensive metabolizer.

    • Received October 30, 2003.
    • Accepted January 13, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (4)
Drug Metabolism and Disposition
Vol. 32, Issue 4
1 Apr 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE O-DEMETHYLATION OF THE DESIGNER DRUG P-METHOXYMETHAMPHETAMINE
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherShort Communication

IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE O-DEMETHYLATION OF THE DESIGNER DRUG P-METHOXYMETHAMPHETAMINE

Roland F. Staack, Denis S. Theobald, Liane D. Paul, Dietmar Springer, Thomas Kraemer and Hans H. Maurer
Drug Metabolism and Disposition April 1, 2004, 32 (4) 379-381; DOI: https://doi.org/10.1124/dmd.32.4.379

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherShort Communication

IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE O-DEMETHYLATION OF THE DESIGNER DRUG P-METHOXYMETHAMPHETAMINE

Roland F. Staack, Denis S. Theobald, Liane D. Paul, Dietmar Springer, Thomas Kraemer and Hans H. Maurer
Drug Metabolism and Disposition April 1, 2004, 32 (4) 379-381; DOI: https://doi.org/10.1124/dmd.32.4.379
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communications

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics